Charles River Laboratories International, Inc. has launched its Endosafe Nexus 200, expanding its endotoxin testing portfolio. The Nexus 200 is the company’s next-gen data integrity compliant, fully robotic instrument, designed to process both undiluted or complex, serial dilutions for water, in-process, and final product testing via Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology in a fully enclosed system. The system allows for data to be exported into a Laboratory Information Management System (LIMS) integration and provides improved traceability, security, and data management on an integrated touch screen using Endosafe EndoScan-V version 6.1.
 
Automation through robotics represents an evolution of bacterial endotoxin testing and streamlines quality control (QC) processes. Smart automation aims to improve overall process efficiency, including: minimizing variation, time, and resources of performing lab investigations;
improving workflow of quality control operations; avoiding the cost and time needed to train individuals to perform repetitive tasks; and reducing the risk for human error in testing processes.
 
Nexus 200 combines technology, innovation, and control to optimize and streamline testing by combining the Endosafe LAL cartridge technology, the Endosafe nexgen-MCS multi-cartridge system, and the Hamilton Microlab Nimbus platforms for a low-maintenance, high-precision walkaway platform. Charles River’s FDA-licensed LAL cartridge is designed to optimize the standard LAL test. All necessary components are included in the self-contained disposable cartridge, including precise amounts of LAL reagent, chromogenic substrate, and control standard endotoxin (CSE). Cartridges are manufactured in accordance with rigid QC procedures and have been approved by the FDA for in-process and final product release testing.
 
“As pharmaceutical manufacturing becomes more efficient, the demand for reliable, compliant, and high-throughput automated bacterial endotoxin solutions increases. Since the launch of Endosafe Nexus in 2014, these demands have inspired our Research and Product Development team to reimagine robotic endotoxin testing with the Endosafe Nexus 200. We are proud of this advancement of our testing portfolio,” said Birgit Girshick, Corporate Executive Vice President & Chief Operating Officer, Charles River.